Johnson Matthey's fine chemicals division reported sales up 15% to £62m in its Q3 ended 31 December 2011. The company said its API manufacturing business performed well aided by sales of a new API for the treatment of drug addiction. Looking forward Matthey said the underlying performance of the division is more predictable and it continues in line with expectations.
Johnson Matthey
Wednesday 1 February 2012
Q3 sales rise at Johnson Matthey
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment